36.10
+0.5(+1.40%)
Currency In USD
| Previous Close | 35.6 |
| Open | 35.42 |
| Day High | 36.11 |
| Day Low | 35.38 |
| 52-Week High | 39.37 |
| 52-Week Low | 25.53 |
| Volume | 81,968 |
| Average Volume | 344,220 |
| Market Cap | 1.99B |
| PE | 33.74 |
| EPS | 1.07 |
| Moving Average 50 Days | 35.68 |
| Moving Average 200 Days | 31.86 |
| Change | 0.5 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $4,173.41 as of December 26, 2024 at a share price of $36.1. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $1,521.28 as of December 26, 2024 at a share price of $36.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2024 10:00 PM GMT
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
GlobeNewswire Inc.
Nov 13, 2024 9:30 PM GMT
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus Announces Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 04, 2024 9:05 PM GMT
Net sales of Qelbree® increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9 million in the third quarter and first nine months of 2024, respectively. Net sales of GOCOVRI® in